Hitachi Selected by the University of Tsukuba for its Second Proton Therapy System as a PFI Project
First-ever additional proton therapy center order from an existing facility in Japan
TOKYO, Nov 22, 2021 - (JCN Newswire) - Hitachi, Ltd. (TSE: 6501) announced today that it has been selected by the University of Tsukuba to provide Hitachi's proton therapy solution including its design, manufacturing, construction, maintenance and operation as a PFI (Private Finance Initiative) project*. The parties have signed the contract on September 30, 2021. The new proton therapy center will be equipped with Hitachi's compact design proton therapy system, including a set of one accelerator and two rotating gantry treatment rooms. The new therapy center is expected to start treating patients around the summer of 2025, followed by a 20-year period of operation and maintenance support by Hitachi.
|Image of New Proton Therapy Center; The new center is on the left of existing site|
The University of Tsukuba has been using Hitachi's proton therapy system since 2001. After 20 years of operation, due to aging facilities, the university has determined to introduce a 2nd unit. Upon completion and opening of the new proton therapy center, the University of Tsukuba will shift its treatment from the existing center to the new center. This is the first time in Japan for a particle therapy system provider to receive a 2nd unit order from an existing facility.
*PFI (Private Finance Initiative) project: Method for utilizing private funds, management skills, and technology in order to construct, operate, and maintain public facilities, etc.
Background and Insight
The University of Tsukuba has been practicing cancer treatment using a proton accelerator since 1983, as a worldwide pioneer. In 2001, the University of Tsukuba adopted Hitachi's proton therapy system and has provided proton therapy to approximately 6,000 cancer patients to date. Hitachi will establish a new proton therapy facility through a strong partnership with the University of Tsukuba which is aiming to be a base for further development of research, education, and treatment for radiotherapy that represents not only Japan, but also the world. In addition, Hitachi and the University of Tsukuba will carry out a joint research program on treatment technologies for pediatric cancer, and tumors of respiratory moving organs (migratory tumors) such as liver and lung cancer. Through this project, Hitachi will contribute to treatment that is gentle to children and the elderly, as well as the maintenance and improvement of patients' quality of life after treatment.
In addition, Hitachi will accelerate the global expansion of particle cancer treatment systems and contribute to the further development of minimally invasive cancer treatments.
Overview of Particle Therapy
Particle Therapy is an advanced type of cancer radiotherapy. Protons extracted from hydrogen atoms, or carbon ions are accelerated up to 70% of the speed of light. This energy is concentrated directly on the tumor while minimizing radiation dose to surrounding healthy tissue. Particle therapy improves the quality of life for cancer patients since the patient experiences no pain during treatment and the procedure has very few side effects compared to that of traditional radiotherapy. In most cases, patients can continue with their normal daily activities while undergoing treatment.
About Hitachi, Ltd.
Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business. Hitachi is focused on strengthening its contribution to the Environment, the Resilience of business and social infrastructure as well as comprehensive programs to enhance Security & Safety. Hitachi resolves the issues faced by customers and society across six domains: IT, Energy, Mobility, Industry, Smart Life and Automotive Systems through its proprietary Lumada solutions. The company's consolidated revenues for fiscal year 2020 (ended March 31, 2021) totaled 8,729.1 billion yen ($78.6 billion), with 871 consolidated subsidiaries and approximately 350,000 employees worldwide. For more information on Hitachi, please visit the company's website at https://www.hitachi.com.
Source: Hitachi, Ltd.
Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
More Latest Release >>
DENSO Announces Organizational Changes in Pursuit of Green, Peace of Mind Causes
Dec 03, 2021 16:10 JST
Olympus Selected for Inclusion in Dow Jones Sustainability World Index (DJSI World)
Dec 03, 2021 09:00 JST
DOCOMO and NEC Successfully Test 5G Standalone with Base Station Conforming to O-RAN Specifications in a Multi-vendor Configuration
Dec 02, 2021 16:50 JST
Mitsubishi Power Upgrades Gas Turbines at Senoko Energy to Reduce 15,000 Tons of Carbon Emissions Annually
Dec 02, 2021 15:44 JST
Honda Selected for 5th Consecutive year to Dow Jones Sustainability Indices World Index
Dec 02, 2021 12:26 JST
Showa Denko Develops Neural Network Models to Predict Mechanical Properties of Aluminum Alloys Accurately
Dec 02, 2021 11:30 JST
MHIENG Receives Order for Compact CO2 Capture System for Biomass Power Plant in Hiroshima
Dec 01, 2021 18:05 JST
NEC Develops High-speed and High-precision Object Detection Acceleration Technology for Edge Equipment
Dec 01, 2021 17:41 JST
Mitsubishi Motors Launches Ralliart Special Editions in Thailand
Nov 30, 2021 17:37 JST
Eisai and FCNT Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia
Nov 30, 2021 10:13 JST
Eisai to Present Latest Data on Perampanel and E2730 at the 75th American Epilepsy Society Annual Meeting
Nov 30, 2021 09:56 JST
Mazda Production and Sales Results for October 2021
Nov 29, 2021 16:58 JST
BOB Financial, NPCI and JCB partner to launch Bank of Baroda Credit Cards on RuPay platform
Nov 29, 2021 16:00 JST
Mazda Included in Dow Jones Sustainability Asia Pacific Index for Fifth Year Running
Nov 29, 2021 14:43 JST
Toyota Releases Sales, Production, and Export Results for October 2021
Nov 29, 2021 13:48 JST
European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) for Patients With Certain Types of Endometrial Carcinoma
Nov 29, 2021 12:44 JST
European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
Nov 29, 2021 10:15 JST
MHI Publishes Integrated Report 'MHI Report 2021'
Nov 26, 2021 18:30 JST
Tokyo Gas, MC to Explore Feasibility of International Synthetic Methane Supply Chain for Carbon Neutrality
Nov 26, 2021 15:01 JST
Honda Unveils the World Premiere of Advanced Future Safety Technologies toward the Realization of its Goal for Zero Traffic Collision Fatalities by 2050
Nov 26, 2021 11:48 JST